UK Committee Urges Clarity On No-Deal Brexit Medicine Supplies
A parliamentary committee has called on the health department to provide more clarity as to how it plans to ensure continuity of medicine supplies in the event of a no-deal Brexit. At the same time, the government has produced a set of draft regulations allowing the UK MHRA to take over drug regulatory functions currently performed at EU level.
You may also be interested in...
The BioIndustry Association wants the government to rule out a “no-deal” Brexit, saying it would be bad for patients and the life sciences sector.
In an effort to address possible serious drug shortages in the event of a no-deal Brexit, the UK government has formally proposed giving pharmacists wide powers to dispense alternative medicines such as different forms, generics, biosimilars, or “therapeutically equivalent” drugs.
The number of new drugs containing new active substances approved in the EU rose significantly in 2020, underpinned by a strong showing for orphan-designated products and a string of novel medicines for cancer and infectious diseases. Notable among the new clutch of approvals was the first ever COVID-19 vaccine, Pfizer/BioNTech's Comirnaty.